BET-inhibitor DYB-41 reduces pulmonary inflammation and local and systemic cytokine levels in LPS-induced acute respiratory distress syndrome: an experimental rodent study

Iten, Manuela; Gschwend, Camille; Ostini, Alessandro; Cameron, David Robert; Goepfert, Christine; Berger, David; Haenggi, Matthias

doi:10.1186/s40635-024-00604-z

Citations

Citation copied

Iten, M., Gschwend, C., Ostini, A., Cameron, D. R., Goepfert, C., Berger, D., & Haenggi, M. (2024). BET-inhibitor DYB-41 reduces pulmonary inflammation and local and systemic cytokine levels in LPS-induced acute respiratory distress syndrome: an experimental rodent study. Intensive Care Medicine Experimental, 12(1), 19. https://doi.org/10.1186/s40635-024-00604-z

Abstract

Background Acute respiratory distress syndrome (ARDS) is a form of respiratory failure stemming from various underlying conditions that ultimately lead to inflammation and lung fibrosis. Bromodomain and Extra-Terminal motif (BET) inhibitors are a class of medications that selectively bind to the bromodomains of BET motif proteins, effectively reducing inflammation. However, the use of BET inhibitors in ARDS treatment has not been previously investigated. In our study, we induced ARDS in rats using endotoxin and administered a BET inhi